JP Morgan Chase
APGE icon

JP Morgan Chase’s Apogee Therapeutics APGE Stock Holding History

JP Morgan Chase’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
+14,900
New +$1.08M ﹤0.01% 4499
2025
Q3 		– Sell
-405,000
Closed -$17.6M – 7375
2025
Q2 		$17.6M Buy
+405,000
New +$15.4M ﹤0.01% 2050

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

JP Morgan Chase's APGE Position: Q1 2026 in Review

JP Morgan Chase reduced its Apogee Therapeutics (APGE) stake by 19% in Q1 2026, selling an estimated $19.1M and leaving 1,110,470 shares worth $87.4M. The position accounts for 0.01% of the portfolio, ranked #1055.

JP Morgan Chase first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $104M in Q4 2025. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • JP Morgan Chase held 1,110,470 shares of Apogee Therapeutics worth $87.4M as of Q1 2026.
  • JP Morgan Chase sold 262,596 Apogee Therapeutics shares in Q1 2026, an estimated $19.1M.
  • Apogee Therapeutics made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1055 holding.
  • JP Morgan Chase first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • JP Morgan Chase's Apogee Therapeutics position peaked at $104M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.